{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:00:13Z","timestamp":1790125213338,"version":"4.0.1"},"reference-count":39,"publisher":"Informa UK Limited","issue":"13","license":[{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Daiichi Sankyo, Inc."}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.2217\/fon-2021-1475","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T09:56:36Z","timestamp":1643795796000},"page":"1595-1607","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":21,"title":["Turalio Risk Evaluation and Mitigation Strategy for Treatment of Tenosynovial Giant Cell Tumor: Framework And Experience"],"prefix":"10.1080","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3641-9738","authenticated-orcid":false,"given":"Charles","family":"Dharmani","sequence":"first","affiliation":[{"name":"Daiichi Sankyo, Inc. 211, Mt. Airy Rd.,\rBasking Ridge, NJ07920, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9937-9959","authenticated-orcid":false,"given":"Eric","family":"Wang","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc. 211, Mt. Airy Rd.,\rBasking Ridge, NJ07920, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5634-1558","authenticated-orcid":false,"given":"Maribel","family":"Salas","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc. 211, Mt. Airy Rd.,\rBasking Ridge, NJ07920, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"McCabe","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center2220 Pierce Avenue, 777 Preston Research Building, Nashville, TN37232, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8831-8405","authenticated-orcid":false,"given":"Alvileen","family":"Diggs","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc. 211, Mt. Airy Rd.,\rBasking Ridge, NJ07920, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3992-5134","authenticated-orcid":false,"given":"Youngsook","family":"Choi","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc. 211, Mt. Airy Rd.,\rBasking Ridge, NJ07920, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9144-5210","authenticated-orcid":false,"given":"Jason","family":"Jiang","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc. 211, Mt. Airy Rd.,\rBasking Ridge, NJ07920, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicki L","family":"Keedy","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center2220 Pierce Avenue, 777 Preston Research Building, Nashville, TN37232, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,2,2]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-020-00993-6"},{"key":"e_1_3_4_4_1","volume-title":"Council for International Organizations of Medical Sciences (CIOMS).","author":"Practical approaches to risk minimisation for medicinal products: report of CIOMS Working Group IX","year":"2014","unstructured":"Practical approaches to risk minimisation for medicinal products: report of CIOMS Working Group IX . Council for International Organizations of Medical Sciences (CIOMS).Geneva, Switzerland (2014)."},{"key":"e_1_3_4_5_1","unstructured":"U.S. Food and Drug Administration . A Framework for Benefit-Risk Counseling to Patients About Drugs with a REMS. www.fda.gov\/media\/107591\/download Accessed 2September2021."},{"key":"e_1_3_4_6_1","unstructured":"U.S. Food and Drug Administration . Risk Evaluation and Mitigation Strategies (REMS). www.fda.gov\/drugs\/drug-safety-and-availability\/risk-evaluation-and-mitigation-strategies-rems (Accessed 2September2021)."},{"key":"e_1_3_4_7_1","unstructured":"U.S. Food and Drug Administration . What's in a REMS. www.fda.gov\/drugs\/risk-evaluation-and-mitigation-strategies-rems\/whats-rems (Accessed 2September2021)."},{"key":"e_1_3_4_8_1","unstructured":"National Organization for Rare Diseases . Tenosynovial Giant Cell Tumor. https:\/\/rarediseases.org\/rare-diseases\/tenosynovial-giant-cell-tumor\/ (Accessed 2September2021)."},{"key":"e_1_3_4_9_1","unstructured":"Turalio [package insert]. Daiichi Sankyo Inc NJ USA (2021)."},{"key":"e_1_3_4_10_1","article-title":"Drug Approval Package: Turalio","author":"\u201cTuralio Risk Evaluation and Mitigation Strategy (REMS) Review\u201d","year":"2019","unstructured":"\u201cTuralio Risk Evaluation and Mitigation Strategy (REMS) Review\u201d . Drug Approval Package: Turalio. FDA Center for Drug Evaluation and Research.2019. www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/211810Orig1s000RiskR.pdf (Accessed 2September2021).","journal-title":"FDA Center for Drug Evaluation and Research."},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30764-0"},{"key":"e_1_3_4_12_1","article-title":"Drug Approval Package: Turalio","author":"\u201cTuralio NDA\/BLA Multi-Disciplinary Review and Evaluation\u201d","year":"2019","unstructured":"\u201cTuralio NDA\/BLA Multi-Disciplinary Review and Evaluation\u201d . Drug Approval Package: Turalio. FDA Center for Drug Evaluation and Research.2019. www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/211810Orig1s000MultidisciplineR.pdf (Accessed 2September2021).","journal-title":"FDA Center for Drug Evaluation and Research."},{"key":"e_1_3_4_13_1","unstructured":"U.S. Food and Drug Administration . Background Materials for REMS Standardization and Evaluation Public Meeting: REMS Evaluation. www.fda.gov\/industry\/prescription-drug-user-fee-amendments\/background-materials-rems-standardization-and-evalution-public-meeting-rems-evaluation (Accessed 2September2021)."},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2020-0253"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2012-0165-CR"},{"key":"e_1_3_4_16_1","first-page":"100","volume-title":"WHO Classification of Tumours of Soft Tissue and Bone. Vol 5. (4th Edition).","author":"de Saint Aubain Somerhausen N","year":"2013","unstructured":"de Saint Aubain Somerhausen N , vande Rijn M. Tenosynovial giant cell tumour, localized type. In: WHO Classification of Tumours of Soft Tissue and Bone. Vol 5. (4th Edition).FletcherCDM, BridgeJA, HogendoornPCW, MertensF (Eds). 100\u2013101IARC Press, Lyon, France (2013)."},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0507321103"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e31802b86f8"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-015-3197-5"},{"key":"e_1_3_4_20_1","first-page":"102","volume-title":"WHO Classification of Tumours of Soft Tissue and Bone. Vol 5. (4th Edition).","author":"de Saint Aubain Somerhausen N","year":"2013","unstructured":"de Saint Aubain Somerhausen N , vande Rijn M. Tenosynovial giant cell tumour, diffuse type. In: WHO Classification of Tumours of Soft Tissue and Bone. Vol 5. (4th Edition).FletcherCDM, BridgeJA, HogendoornPCW, MertensF (Eds). 102\u2013103IARC Press, Lyon, France (2013)."},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.2106\/00004623-198466010-00012"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2010.07.005"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-015-0385-x"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/17453674.2017.1361126"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e328347e1e3"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2014.06.025"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70035-9"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.03.008"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon.13.124"},{"key":"e_1_3_4_30_1","first-page":"e50","article-title":"Giant cell tumor of the tendon sheath: experience with 65 cases","volume":"12","author":"Adams EL","year":"2012","unstructured":"Adams EL , YoderEM, KasdanML. Giant cell tumor of the tendon sheath: experience with 65 cases. Eplasty12, e50 (2012).","journal-title":"Eplasty"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.bpo.0000242380.95348.8b"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhsu.1999.1298"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.23220"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000019856"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12593-010-0020-9"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1054\/jhsb.2000.0522"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0266-7681(98)80084-3"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-3967"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26409"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33312"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.11.007"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2021-1475","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:43:25Z","timestamp":1719125005000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2021-1475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,2]]},"references-count":39,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.2217\/fon-2021-1475"],"URL":"https:\/\/doi.org\/10.2217\/fon-2021-1475","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-11-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}